|
TalkPoint and Life Technologies Partner for Flow Session |
|
Wednesday, 11 January 2012 |
TalkPoint and Life Technologies Partner for the Second Session of the Flow Cytometric Analysis Series
The webinar series provides an overview of the tools and techniques using Molecular Probes® Reagents.
TalkPoint, the leader in global communications technology, specializing in browser-based audio and video webcasting, and Life Technologies, a global biotechnology company dedicated to improving the human condition, are partnering again to present part two of the series titled “An Introduction to Flow Cytometric Analysis Using Molecular Probes® Reagents.”
The second part of the series will be held on Thursday, January 12, from 10:00 a.m. - 11:00 a.m. PT.
The TalkPoint powered webinar will provide an overview of the tools and techniques of Molecular Probes® reagents for flow cytometric analysis of cell proliferation, viability, vitality and apoptosis.
During the free webinar, Jolene Bradford, MLS (ASCP) CM, R&D associate director of flow cytometry systems at Life Technologies, will lend her expertise to the discussion. The following topic areas will be discussed in the continuation of the series:
- Flow cytometric analysis of apoptosis and identification of dead cells
- Changes introduced by apoptosis that can be tested with numerous assays measuring membrane structure, mitochondrial function, metabolism, Caspase activity, membrane integrity and DNA fragmentation
- Dead cell identification using traditional impermeant nucleic acid dyes
|
|
Try something new, you just might like it |
|
Tuesday, 13 December 2011 |
Thinking of trying a new reagent but don't want to risk the precious lab budget?
Bioss USA has a free sample program for selected reagents to help you ease into their 5500+ flow cytometry reagents. Check em out.
|
|
|
Affymetrix Buying Flow Cytometry, Reagent Firm eBioscience for $330M |
|
Wednesday, 23 November 2011 |
|
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Affymetrix today announced a definitive
agreement to buy eBioscience, a flow cytometry and immunoassay reagent
firm, for $330 million in cash.
The deal is expected to provide the Santa Clara, Calif.-based
microarray firm with commercial opportunities in post-genomic
applications of immunology, oncology, cell biology, stem cell biology,
and diagnostics. Affy also said that it will augment its growing
molecular diagnostics business.
The deal will diversify Affy's revenues "to complement its genomics
franchise," and expand its product portfolio to include multicolor flow
cytometry reagents, as well as reagents for research into cytokines,
growth factors, and other soluble proteins, it said.
Affy expects the acquisition to "expand operational and new product
opportunities for Panomics RNA and protein analysis products," and
generate new growth opportunities by leveraging the commercial abilities
of both firms.
In a research note, RW Baird analyst Quintin Lai said today that the
deal is "a major step in transforming [Affymetrix] and specifically
moving it away from a microarray business." He voiced, however, concerns
about the price Affy is paying and the possibility that it "could limit
the company's flexibility into the near term for future deals."
Calling the transaction "transformational" Affy President and CEO
Frank Witney said in a statement that the cell-based and immunoassays
provided by the acquisition "are a critical part of our customers'
workflow in our key target markets of translational medicine, oncology,
and immunology. We believe that these markets represent a nearly [$3
billion] annual opportunity, which will put Affymetrix on a solid path
to sustained growth and profitability."
|
|
|
Accuri Cytometers receives technology award |
|
Thursday, 10 November 2011 |
|
BD’s acquisition of Accuri, announced in February, came less than two years after its $275 million acquisition of Pittsfield Township-based HandyLab, another medical device maker.
Although BD shut down HandyLab, local executives are optimistic that Accuri will not face the same fate.
Jeff Williams, who served as CEO of both companies at the time they were sold, told AnnArbor.com in April that Accuri was “doing great.”
"BD has significant plans for the Accuri brand, as well as for the
facility here,” said Williams, who now serves as CEO of Ann Arbor-based Life Magnetics and Tangent Medical Technologies. “I think it’s a very exciting time for Accuri."
Accuri, whose device reshaped how life sciences researchers analyze
cell flow, was named Friday as the winner of the Technology award at AnnArbor.com Business Review’s 2011 Deals of the Year ceremony.
Accuri’s sale marked the second largest publicly disclosed sale price for a local tech company over the last 10 years, after HandyLab’s acquisition and Pfizer Inc.'s $1.3 billion acquisition of drug development firm Esperion Therapeutics in 2004.
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
